{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:22:02Z","timestamp":1792120922315,"version":"4.4.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            represents a major cause of health care-associated infections, and inappropriate initial antimicrobial therapy is associated with increased morbidity and mortality. The International Network for Optimal Resistance Monitoring (INFORM) program monitors the\n            <jats:italic>in vitro<\/jats:italic>\n            activity of ceftazidime-avibactam and many comparator agents. We evaluated the antimicrobial susceptibility of 7,452\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            isolates collected from 79 U.S. medical centers in 2012 to 2015. The isolates were collected and tested consecutively for susceptibility by broth microdilution method. Infection types included mainly pneumonia (50.5%), skin and skin structure (24.0%), urinary tract (7.8%), and bloodstream (7.7%) infections. The only compounds with &gt;90% susceptibility rates were colistin (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 1\/2 mg\/liter, respectively; 99.4% susceptible), ceftazidime-avibactam (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 2\/4 mg\/liter, respectively; 97.0% susceptible), and amikacin (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 2\/8 mg\/liter, respectively; 97.0\/93.0% susceptible [CLSI\/EUCAST, respectively]). The addition of avibactam to ceftazidime increased the percentage of susceptible\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            isolates from 84.3% to 97.0%. Multidrug resistance (MDR) and extensive drug resistance (XDR) phenotypes were observed among 1,151 (15.4%) and 698 (9.4%) isolates, respectively, and ceftazidime-avibactam inhibited 82.1 and 75.8% of these isolates at \u22648 mg\/liter, respectively. High rates of cross-resistance were observed with ceftazidime, meropenem, and piperacillin-tazobactam, whereas ceftazidime-avibactam retained activity against isolates nonsusceptible to ceftazidime (81.0% susceptible), meropenem (86.2% susceptible), and piperacillin-tazobactam (85.4% susceptible), as well as isolates nonsusceptible to these three \u03b2-lactams (71.2% susceptible). The only antimicrobial combinations that provided a better overall anti-\n            <jats:named-content content-type=\"genus-species\">Pseudomonas<\/jats:named-content>\n            coverage than ceftazidime-avibactam (97.0% susceptibility rate) were those including amikacin (97.0 to 98.4% coverage). Susceptibility rates remained stable during the study period. The results of this investigation highlight the challenge of optimizing empirical antimicrobial therapy for\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            infections.\n          <\/jats:p>","DOI":"10.1128\/aac.02252-16","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T02:30:27Z","timestamp":1484015427000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":114,"title":["Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States"],"prefix":"10.1128","volume":"61","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. 2016. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/338782"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.06.015"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.02.022"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.08.011"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03056-15"},{"key":"e_1_3_2_11_2","volume-title":"Avycaz (ceftazidime-avibactam) package insert","author":"Actavis","year":"2015","unstructured":"Actavis. 2015. Avycaz (ceftazidime-avibactam) package insert. Actavis, Dublin, Ireland. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206494s000lbl.pdf."},{"key":"e_1_3_2_12_2","volume-title":"Zavicefta package insert","author":"AstraZeneca AB","year":"2016","unstructured":"AstraZeneca AB . 2016. Zavicefta package insert. AstraZeneca AB, S\u00f6dert\u00e4lje, Sweden. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_14_2","volume-title":"National Healthcare Safety Network","author":"National Healthcare Safety Network","year":"2016","unstructured":"National Healthcare Safety Network. 2016. Data on antibiotic-resistant healthcare-associated infections, 2012\u20132014. National Healthcare Safety Network, Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/gis.cdc.gov\/grasp\/PSA\/index.html."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.11.1073"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2756-2764.2003"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(98)00060-0"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05041-11"},{"key":"e_1_3_2_19_2","volume-title":"M100-S26","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","volume-title":"M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th edition. M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_21_2","unstructured":"EUCAST. January2017. Breakpoint tables for interpretation of MICs and zone diameters version 7.0. http:\/\/www.eucast.org\/clinical_breakpoints\/."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02252-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02252-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:46:50Z","timestamp":1645476410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02252-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1128\/AAC.02252-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02252-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2016-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02252-16"}}